Dr. Anjlee Mahajan, MD

Dr. Mahajan practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Mahajan's NPI, 1356578454, was assigned on June 16, 2009. Dr. Mahajan graduated from Albert Einstein College of Medicine in 2009. Dr. Mahajan holds California license A114379.

Dr. Mahajan's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Mahajan's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is The Permanente Medical Group, Inc. Dmand AI also links Dr. Mahajan to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mahajan practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Mahajan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Mahajan is board certified in hematology by the American Board of Internal Medicine. Dr. Mahajan is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), lung cancer, lymphoma and multiple myeloma among the conditions Dr. Mahajan treats.

CMS data shows 470 Medicare services from Dr. Mahajan across 10 procedure codes in 2024, for 251 Medicare patients. Medicare paid $34,718 for them.

CMS counts 251 Medicare patients who saw Dr. Mahajan in 2024. The largest group is 65 to 74, with 94 patients. 75% of them have high blood pressure, and 67% have high cholesterol. 33% are also on Medicaid. Their average risk score is 2.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mahajan's median patient age at 58, with 56% women.

In 2024, Dr. Mahajan wrote 1,415 Medicare Part D claims for 439 patients. 89% of them were for generic drugs. CMS names the drug for 1,395 of them, across 5 drugs with 11 or more claims each, at $189,582 in total drug cost. In 2023, CMS named 1,369 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Mahajan for performance year 2024, reported as part of a group. Dr. Mahajan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mahajan as offering telehealth.

Dmand AI links 24 papers to Dr. Mahajan, published from 2017 to 2025. 2017 was the busiest year, with 2. The most frequent topics are Venous Thromboembolism, Anemia, Sickle Cell and Anticoagulants. Dr. Mahajan has published most often in Blood Adv. Dr. Mahajan's most frequent co-authors are Theodore Wun, MD, Oyebimpe Oluyemisi Adesina, MD and Michael R. Debaun, MD.

Dmand AI links Dr. Mahajan to 1 clinical trial. Conditions studied include Antiphospholipid Syndrome and Thrombosis.

CMS Open Payments shows 18 general payments to Dr. Mahajan from 8 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 90% of the total. Genentech, Inc. paid the most, $13,337.

Dr. Mahajan graduated from Albert Einstein College of Medicine in 2009.

Dr. Mahajan is in network with 5 carriers, including Aetna, United Healthcare and Blue Cross and Blue Shield of Kansas City. Medicare plans come from the most carriers, 3. Check the plan with the practice before a visit.